Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024.
波士顿，2024年11月25日，环球新闻社报道--cue biopharma，Inc.（纳斯达克：CUE），一家开发新型治疗生物制品以选择性地激活和调节特定疾病t细胞治疗癌症和自身免疫疾病的临床阶段生物制品公司，今天宣布将参加将于2024年12月3日至5日在纽约举行的派杰投资第36届医疗保健大会上的一场未播放的炉边讨论。
During the fireside discussion, Cue Biopharma will provide an overview highlighting recent clinical and preclinical program updates as well as strategic business and partnering model objectives.
在炉边讨论期间，cue biopharma将概述最近的临床和临床前计划更新以及战略业务和合作伙伴模式目标。
Presentation Details
Date and Time: Wednesday, December 4, 2024, from 9 a.m. EST – 9:25 a.m. EST
Webcast Link:
Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
报告详情
日期和时间：2024年12月4日，从美国东部时间上午9点至上午9点25分。
网络广播链接：
Presenter: Daniel Passeri万.Sc., J.D., chief executive officer, Cue Biopharma
A live and archived webcast of the fireside discussion will be available on the Events page in the Investors and Media section of the Company's website at . The webcast will be archived for 30 days.
公司网站的投资者与媒体部分的事件页面将提供有关围炉讨论的现场直播和存档网络广播。该网络广播将存档30天。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
关于cue biopharma
Cue生物制品是一家处于临床阶段的生物制品公司，正在开发一种新型类注射生物制品，可选择性地干预和调节病特异性t细胞，直接作用于患者体内。该公司专有的平台Immuno-STAt（t细胞的选择性靶向和改变）以及生物制品旨在通过选择性调节病特异性t细胞，而无需进行全面系统性免疫调节，利用体内免疫系统的治愈潜力。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
总部位于马萨诸塞州的波士顿，我们由一支经验丰富的管理团队和独立的董事会领导，拥有在免疫学、免疫肿瘤学以及蛋白质生物制品的设计和临床开发方面的深厚专业知识。
For more information please visit and follow us on X and LinkedIn.
Marie Campinell 高级总监，企业传讯 Cue Biopharma, Inc.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投资者联系方式
Marie Campinell
高级董事，企业通信
cue biopharma，全球货币
mcampinell@cuebiopharma.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒体联系
Jonathan Pappas
通信-半导体
jpappas@lifescicomms.com
